30 results about "RUNX2" patented technology

Provided herein are methods and compositions for differentiating induced pluripotent stem cells into granulosa-like cells by overexpressing transcription factors such as NR5A1 and a RUNX family protein (e.g., RUNXI and / or RUNX2).

The invention discloses a sterone compound derived from achyranthes bidentata as well as a preparation method and application of the sterone compound. Belongs to the technical field of biological medicine. The invention aims to solve various side effects and defects of the existing medicine for treating glucocorticoid-induced osteoporosis in long-term use. The molecular formula of the compound (SSA) is C33H48O9, the compound (SSA) has a beta-ecdysterone skeleton, and acetal type 5-hydroxymethylfurfural groups are introduced at the positions of side chains C20 and C22. SSA has a remarkable protection effect in a DEX-induced osteoblast injury model, can improve cell viability decline and G1 phase retardation caused by glucocorticoid, and recovers osteogenic differentiation and mineralization ability. The SSA effectively reverses the inhibition effect of DEX on osteoblasts by activating a Wnt / beta-catenin signal channel and up-regulating the expression of RUNX2. SSA has a remarkable anti-osteoporosis function potential.

The invention relates to application of harmine in preparation of a medicine for preventing and treating vascular calcification. The harmine can be used for preventing and / or treating vascular calcification. Experiments show that harmine reduces osteogenic differentiation of vascular smooth muscle cells by down-regulating expression of RUNX2 and BMP2 and up-regulating expression of alpha-SMA at the same time, calcium salt deposition of blood vessels can be reduced, and it is indicated that harmine has a remarkable inhibition effect on vascular calcification. The new application of harmine in the anti-vascular calcification aspect is confirmed, so that the research of harmine in the technical field of medicines can be expanded, a new way is provided for research and development of drugs for treating vascular calcification, and a new theoretical direction is provided for clinical application.

This invention relates to the field of biomedical technology, specifically disclosing an anti-inflammatory and bone-promoting rhodioloside composite hydrogel and its preparation method. The thermosensitive carrier is a triple-response system, which enhances the drug release rate only in a specific microenvironment at 37°C, with a pH of 5.5-6.5 at the site of inflammation, and in which MMPs are overexpressed. MMPs are highly expressed at the implant periodontitis site, and MMP-sensitive peptides can be specifically degraded by this enzyme. This process can trigger the precise release of rhodioloside and quercetin active ingredients in the gel, avoiding systemic drug diffusion that could lead to drug waste or side effects at other sites. Rhodioloside and quercetin synergistically downregulate the expression levels of inflammatory factors such as IL-6 and TNF-α, while nisin and chitosan-ε-polylysine grafts inhibit the growth of Porphyromonas gingivalis. Runx2 / CON expression is increased, achieving a closed-loop treatment of anti-inflammatory, antibacterial, and bone-promoting effects.

This invention belongs to the field of biomedical technology and relates to the application of OSM inhibitors in the preparation of drugs for the prevention or treatment of calcific aortic valve disease. This invention reveals for the first time that OSM drives osteogenic differentiation and calcified nodule formation of valvular interstitial cells through the OSM-OSMR-JAK2 / JAK3-STAT3-RUNX2 signaling axis, which is the core pathogenic mechanism leading to calcific aortic valve disease. This invention utilizes anti-OSM neutralizing antibodies or sulforaphane to effectively block this signaling axis, significantly inhibiting macrophage infiltration, valvular calcification, and improving hemodynamic abnormalities. This invention provides a precise target and a novel strategy for the modification therapy of calcific aortic valve disease, solving the technical problem of the ineffectiveness of traditional broad-spectrum anti-inflammatory therapy in valvular calcification.

The present invention relates to novel long non-coding RNAs (lncRNA) involved in the regulation of hypertrophy of chondrocytes, wherein RUNX2 was regulated at the post-translational level during hypertrophic differentiation of the chondrocyte cell line TC28a2 and two novel RUNX2-binding lncRNAs among numerous lncRNAs were identified, leading to the present invention. It is expected that bone-related diseases can be diagnosed by measuring the expression of the identified specific lncRNAs, and furthermore, the vascularization or calcification of articular cartilage can be effectively suppressed by inhibiting the hypertrophy of chondrocytes through inhibiting the expression of the identified specific lncRNAs, which is expected to be highly effective in the prevention or treatment of bone-related diseases.

The invention provides an embryonic stem cell differentiation technology and application of the embryonic stem cell differentiation technology in screening of unknown risk alternative toxicity of a novel biological breeding product, and Cry1Ab protein is used as a test substance to evaluate the developmental toxicity of the Cry1Ab protein. The EBs are generated through hanging drop culture, and bone differentiation induction substances (beta-glycerophosphate, ascorbic acid and vitamin D3) are added to promote differentiation of the EBs. After bone cell induced differentiation is finished, the differentiation condition of bone cells is observed through alizarin red S dyeing and absorbance value detection, the cell growth condition is observed through cell total protein concentration and alkaline phosphatase activity detection, and then the influence of a test substance on the bone differentiation process is analyzed through the gene expression condition of osteogenic differentiation related markers (Runx2, SPARC and I-type collagen). The invention solves the problem of evaluating the unknown risk of a novel biological breeding product in vitro, creates an embryonic stem cell bone differentiation test technology, and uses the embryonic stem cell bone differentiation test technology as a screening method for the unknown risk alternative toxicity of the novel biological breeding product to be combined with an embryonic stem cell myocardial differentiation experiment for use. And the accuracy of predicating the developmental toxicity of the test substance is improved.

Provided are a prophylactic or therapeutic agent for Crohn's disease, and a method for examining Crohn's disease. The prophylactic or therapeutic agent for Crohn's disease contains at least one selected from the group consisting of a RUNX2 inhibitor and a BHLHE40 inhibitor. The method for examining Crohn's disease includes (1) a step for detecting a protein and / or mRNA of at least one gene selected from the group consisting of RUNX2 and BHLHE40 in digestive tract-derived immune cells collected from a subject.

The present invention belongs to the field of biomedicine, and specifically relates to the use of reagents that knock down or inhibit ANT1 in the preparation of drugs for preventing and / or treating heterotopic ossification. The present invention is the first to discover the use of reagents that knock down or inhibit ANT1 in the preparation of drugs for preventing and / or treating heterotopic ossification. Inhibiting ANT1 can significantly reduce heterotopic ossification formed after soft tissue injury; reduce the infiltration of osteoblasts, chondrocytes, and inflammatory cells in damaged tendons, reduce bone marrow cavity and blood vessel formation, and reduce bone tissue formation; significantly inhibit the expression of osteoblast-related markers OCN, RUNX2, and ALP in injured tendons; and can effectively prevent and / or treat heterotopic ossification.

The present application relates to the field of medicine biotechnology, especially the application of RUNX2 as a marker in the preparation of a breast malignant phyllodes tumor diagnosis or detection reagent. The reagent can assist conventional biopsy according to the expression level of RUNX2 in different grades of breast phyllodes tumor, and can diagnose, differentially diagnose, grade and prognostically analyze the breast phyllodes tumor. The RUNX2 detection primer sequence and detection antibody of the present application are important components of the diagnosis or detection reagent or kit, so that the detection of breast malignant phyllodes tumor is more simple, fast and accurate, has good clinical application value, helps to further improve the diagnosis level of breast malignant phyllodes tumor, and is expected to become the first diagnosis and detection kit for breast malignant phyllodes tumor.

The invention relates to the technical field of biological treatment of bone metabolic diseases, and discloses an application of a bone-strengthening and blood-generating oral liquid in preparation of a medicine for treating osteoporotic fracture.The application includes the steps that when the medicine is prepared, active components in the bone-strengthening and blood-generating oral liquid are combined with a Wnt signal transduction complex in osteoblasts in a targeted mode, and the bone-strengthening and blood-generating oral liquid is obtained; the phosphorylation activity of glycogen synthase kinase-3 is inhibited, so that-catenin enters a nucleus, Runx2 expression is started, and the synthesis rate of the N-terminal propeptide of the type I procollagen is increased; according to the method, a positive anabolism window is established in an original callus formation period of fracture healing by constructing an osteogenesis and osteoclast activity two-way decoupling biological regulation mechanism, so that a positive anabolism effect is achieved, and a positive anabolism effect is achieved. Bone metabolism pathological deviation in an osteoporosis state is corrected, secondary absorption of callus is inhibited while high osteogenic activity is maintained, and biomechanical fracture load of bones after fracture healing is improved.

The application belongs to the technical field of medicine, and particularly relates to application of alpha-ketobutyric acid in preparation of a medicine for preventing and / or treating vascular calcification. Through a high-phosphorus-induced vascular smooth muscle cell calcification model and a vitamin D3-induced mouse aorta calcification model, the application first proves that alpha-ketobutyric acid can significantly inhibit vascular calcium salt deposition, reduce osteogenic-like transdifferentiation of vascular smooth muscle cells, and down-regulate expression of osteogenic-related markers such as RUNX2 and BMP2. In addition, alpha-ketobutyric acid and sodium hydrosulfide in combination show a synergistic effect. The application provides a new medicine selection and strategy for prevention and treatment of vascular calcification and related cardiovascular diseases.

The invention discloses a biomarker related to senescence of mesenchymal stem cells and application of the biomarker, and belongs to the field of biomarkers. The biomarker comprises a characteristic gene set consisting of 22 genes, wherein the characteristic gene set comprises MCF2L, PSG5, IGFBP5, LMNTD1, ANKRD29, F3, SCN9A, IL6, CDKN3, TENM2, TGFB2, DUSP1, TMEM47, IGFBP3, EEF1E1, SCN3A, ANKRD1, NGF, VCAM1, PDGFRL, EGR1 and RUNX2. When the biomarker provided by the invention is used for constructing an MSC aging prediction model, not only can sequential aging caused by in-vitro artificial amplification of the MSC be evaluated, but also the aging state of MSCs from different donors or tissues can be predicted, and an effective tool is provided for quality control and screening of preclinical MSCs.

The application discloses a PLGA microsphere-PCL / GelMA composite scaffold based on nerve growth factor (NGF) sustained release and a preparation method and application thereof. The composite scaffold is constructed by embedding the NGF-loaded PLGA microsphere into the PCL framework and the GelMA hydrogel matrix, and a three-phase composite system with mechanical support, sustained release of biological factors and cell adhesion function is constructed. In vitro experiments show that the NGF-loaded composite scaffold significantly promotes the osteogenic differentiation of dental pulp stem cells, and the alkaline phosphatase activity is improved, the formation of mineralized nodules is increased, and the expression of osteogenesis-related genes RUNX2 , ALPL , COL1A1 and BGLAP is up-regulated. When applied to a rat skull critical defect model in vivo, the composite scaffold significantly promotes new bone formation and vascular nerve regeneration. Mechanism research shows that it realizes the regulation of osteogenesis and bone resorption by activating the PI3K / AKT signaling pathway. The composite scaffold is suitable for the repair of complex bone defects in the region rich in nerves and blood vessels, and has good clinical application prospect.

The invention discloses a antler active peptide fragment as well as a preparation method and application thereof, and relates to the technical field of biological peptides. The amino acid sequence of the antler active peptide fragment is NGYDFGFDGDFYAR, and the antler active peptide fragment not only has the effect of promoting proliferation of osteoblasts, but also can inhibit reduction of cell viability and relieve osteoblast damage. Meanwhile, the antler active peptide fragment can effectively antagonize DEX-induced ferroptosis and recover the physiological function of osteoblasts to a certain extent. Specifically, the antler active peptide fragment can reduce the ROS level of osteoblasts, reduce the MDA and LPO content and iron ion accumulation, and promote the expression of osteogenic proteins Runx2 and Osterix in osteoblasts and the callback of ferroptosis proteins SLC7A11 and GPX4.

Provided herein are methods and compositions for differentiating induced pluripotent stem cells into granulosa-like cells by overexpressing transcription factors such as NR5A1 and a RUNX family protein (e.g., RUNX1 and / or RUNX2).

The invention discloses a nucleic acid aptamer of RUNX2 protein and application of the nucleic acid aptamer, and belongs to the technical field of biology, the nucleotide sequence of the nucleic acid aptamer is shown as SEQ ID NO.1, the nucleic acid aptamer has the advantages of being small in molecular weight, stable in chemical property, easy to store and mark and the like, the nucleic acid aptamer is obtained through screening based on the SELEX technology, the nucleic acid aptamer can be combined with the RUNX2 protein with high affinity and high specificity, and the nucleic acid aptamer can be used for detecting the RUNX2 protein. The affinity constant is as low as 8.88 nM, and the synthesis cost is low. The nucleic acid aptamer provided by the invention shows good application prospects in the aspects of disease detection, diagnosis, molecular imaging, targeted therapy and the like.

The invention discloses application of GDF6 in preparation of a medicine for detecting periodontitis or preventing and treating periodontitis, and belongs to the technical field of biological medicine. The invention finds that GDF6 is obviously reduced in periodontitis gingival tissues; the GDF6 can improve the expression of ALP, cell mineralization and the expression of osteogenic transformation related genes ALP, RUNX2 and OCN by reducing the expression of inflammatory factors of the inflammatory PDLSCs, so that the GDF6 can be used for osteogenic differentiation of the PDLSCs in an inflammatory state. In addition, the GDF6 can significantly improve the level of periodontitis of mice and alveolar bone resorption when applied in vivo, so that the GDF6 has a good treatment effect on periodontitis.

The invention discloses application of a quasi-kinesization modification inhibitor in preparation of a medicine for preventing and / or treating vascular calcification of chronic kidney diseases. The micafungin serving as a metalloid modification inhibitor inhibits osteogenic transdifferentiation of vascular smooth muscle cells, reduces the expression of an osteogenic factor RUNX2 and increases the expression of a contraction marker alpha-SMA of the vascular smooth muscle cells. Meanwhile, calcium salt deposition of vascular smooth muscle cells is remarkably inhibited. It is found for the first time that micafungin can play a role in protecting CKD vascular calcification independent of the antifungal effect of micafungin. The discovery provides a new hope for prevention and treatment of CKD vascular calcification.

This invention discloses a specific expression regulatory element for the hornless target gene RXFP2 in goats and its application. The sequence of the regulatory element is SEQ ID No. 1. Through single-cell gene expression and chromatin accessibility analysis of fetal bovine horn bud tissue, this invention discovered a specific, open regulatory element (chr12:29279059-29279559) upstream of RXFP2 in horn bud tissue. This element possesses a binding motif for RUNX2, a core transcription factor promoting osteoprogenitor cell differentiation, and is highly conserved in horned animals. Its location in the goat genome is chr12:57440948-57441449. Dual-luciferase assays verified that this regulatory element mediates the interaction between transcription factors RUNX2 and RXFP2, achieving specific high expression of RXFP2 in horn bud tissue. By knocking out the regulatory element region (chr12:57440800-57441678) in goat embryos using CRISPR-Cas9, goat embryos with gene-edited knockout of the hornless target gene RXFP2 specifically expressing regulatory elements were successfully prepared. This invention further elucidates the origin, evolution, and skin ossification mechanisms of horn organs, providing new targets for hornless livestock breeding.

The invention discloses a detection kit for a dwarf disease-causing gene, the detection kit comprises a library building reagent, a hybridization capture reagent and a probe, and the probe covers exon and intron regions of FGFR3, PTPN11, NF1, PHEX, ACAN, COL2A1, KMT2A, NIPBL, COL1A1, RUNX2, ANKRD11, SHOX, GH1, COMP, KMT2D, IGF1R, SHOC2, SOX11, NPR2, IHH, GHR and IGF1 genes. According to the invention, exon and intron regions of 23 genes can be specifically recognized, diagnosis of genetic etiology is realized, and the kit has important significance for subsequent treatment of child patients. Sanger method sequencing does not need to be carried out on all exons, the detection time is short, and the detection cost is low.

The invention belongs to the technical field of microorganisms and provides lactococcus lactis with remarkable bone strengthening activity and application of the lactococcus lactis 3-1, the lactococcus lactis 3-1 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.34671, and the preservation date is May 26, 2025. Fermentation supernate of the strain can produce butyric acid, can promote calcium nodule formation and up-regulate expression of osteogenic differentiation genes RUNX2, BGLAP and ALP, and has stable fermentation performance and gastric acid and cholate tolerance. By optimizing the process, the method is successfully applied to preparation of the sheep cheese. Animal experiments show that the strain and the sheep cheese fermented by the strain can improve osteoporosis symptoms of tail suspension rats, promote bone trabecula remodeling and mineralization, improve bone mineral density and bone biomechanical properties, regulate osteogenesis / osteoclast activity and increase the content of butyric acid in cecum contents, and have application potential in the field of osteoporosis prevention and treatment.

The invention discloses a PLGA microsphere-PCL / GelMA composite scaffold based on neurotrophic factor (NGF) slow release as well as a preparation method and application of the PLGA microsphere-PCL / GelMA composite scaffold. According to the composite scaffold, NGF-loaded PLGA microspheres are embedded into a PCL skeleton and a GelMA hydrogel matrix, and a three-phase composite system with mechanical support, biological factor sustained release and cell adhesion functions is constructed. In-vitro experiments show that the NGF-loaded composite scaffold can significantly promote osteogenic differentiation of dental pulp stem cells, which shows that the activity of alkaline phosphatase is improved, the formation of mineralized nodules is increased, and the expression of osteogenic related genes RUNX2, ALPL, COL1A1 and BGLAP is up-regulated. When the composite stent is applied to a rat skull critical defect model in vivo, new bone formation and vascular nerve regeneration are remarkably promoted. Mechanism research shows that regulation and control of osteogenesis and bone resorption are realized by activating a PI3K / AKT signal channel. The composite stent is suitable for repairing complex bone defects in areas with rich nerves and blood vessels, and has a good clinical application prospect.

The invention discloses a lung targeting nucleic acid drug-carrier composition, a preparation method and application, and belongs to the technical field of biological medicine. The composition takes an FEN1-DNP deoxyribonucleoprotein compound as a core treatment component, the compound is formed by assembling FEN1 endonuclease and an hpDNA oligonucleotide probe, the pulmonary fibrosis core pathogenic genes RUNX2 and PAI-1 can be precisely cut in a targeted manner, and the pathological process of a disease is cooperatively intervened in multiple links. A delivery carrier adopts composite lipid nanoparticles composed of ionized lipid, cationic lipid, neutral phospholipid, cholesterol and pegylated lipid, an FEN1-DNP compound is efficiently entrapped through a microfluidic method, and the composition adapts to aerosol inhalation administration, can directly reach a lung focus, improves the drug lung tissue enrichment degree, reduces the toxicity of non-target organs of the whole body, and has a good application prospect. The method has the advantages of multi-target intervention, high targeting and high biological safety, and has remarkable clinical transformation potential in the field of pulmonary fibrosis treatment.

The application provides application of ipomoea nil exocyst in preparation of a medicine for preventing, alleviating or treating osteomyelitis. The application creatively finds that the ipomoea nil exocyst can significantly inhibit the expression of macrophage pyroptosis markers GSDMD-NT and Caspase-1, promote the expression of osteogenesis markers RUNX2 and OPN, and mediate immune regulation to achieve the treatment of osteomyelitis. The ipomoea nil exocyst is loaded in a three-dimensional cross-linked skeleton formed by oxidized dextran, aminopolysaccharide and gelatin, has better mass transfer delivery effect, and significantly improves the treatment effect on osteomyelitis.

The application discloses an allicol oligosaccharide as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. Alkaline phosphatase staining and alizarin red staining tests prove that the allicol oligosaccharide AMO-1 can significantly improve the activity level of alkaline phosphatase in MC3T3 cells and osteogenic mineralization nodules, and can significantly up-regulate the expression levels of osteogenic differentiation related proteins RUNX2, OSX, OCN and COL1; animal experiments prove that AMO-1 can obviously relieve bone loss of DEX-induced osteoporosis mice, and can be used for preparing medicines for preventing and treating osteoporosis. The oligosaccharide provided by the application has high purity, does not contain impurities such as proteins and nucleic acids, has small toxic and side effects, has a wide application prospect in preparation of low-toxicity and high-efficiency anti-osteoporosis medicines, and is favorable for further development and utilization of allicol resources.

The invention belongs to the field of stem cell genetic engineering, and provides application of NLRP12 in anti-inflammatory osteogenesis promotion of periodontal ligament stem cells. According to the NLRP12 overexpression PDLSCs, the anti-inflammatory gene is applied to periodontal regeneration treatment, and the anti-inflammatory capacity and the tissue defect repairing capacity after the PDLSCs are transplanted into a body are effectively improved. An exogenous gene is transferred into PDLSCs through a virus vector, stable transfection and efficient and continuous expression of an anti-inflammatory gene are achieved, and the repair effect of periodontitis tissue defects is promoted. In-vitro experiments show that NLRP12 overexpression in an inflammatory microenvironment alleviates the inflammatory response and osteogenic differentiation inhibition of PDLSCs, which shows that the expression of proinflammatory factors IL-6 and IL-8 is down-regulated, the expression levels of anti-inflammatory factors IL-10 and osteogenic related proteins RUNX2, COL1 and BMP2 are up-regulated, ALP dyeing and alizarin red dyeing are deepened, and mineralized nodule formation is increased. The NLRP12 overexpression PDLSCs is applied to a rat experimental periodontitis model in vivo, inflammatory reaction is remarkably relieved, and periodontal tissue regeneration of periodontitis rats is promoted. Mechanism research shows that the NLRP12 alleviates the inflammatory response of PDLSCs and osteogenic differentiation inhibition by inhibiting an NF-kappa B pathway. The NLRP12 overexpression PDLSCs are suitable for repairing periodontal tissue defects, and have a good clinical application prospect.

The application discloses application of Phascolosoma esculenta exosome in preparation of a preparation for promoting osteogenic differentiation of bone marrow mesenchymal stem cells, and belongs to the technical field of marine biological medical materials. Fresh and live Phascolosoma esculenta is used as raw material, body cavity fluid is collected, and Phascolosoma esculenta exosome is obtained through separation and purification by means of fractional filtration, differential centrifugation and ultracentrifugation. The exosome has uniform particle size, high biocompatibility and no cytotoxicity, can significantly promote proliferation of human bone marrow mesenchymal stem cells in a low concentration range of 5-10 μg / mL, up-regulate expression levels of ALP, RUNX2 and OPN osteogenic marker proteins, improve alkaline phosphatase activity, promote calcium nodule deposition, accelerate osteogenic differentiation of stem cells, and has good biological medicine development prospect and industrial application value.

The invention belongs to the technical field of medicines, and particularly relates to application of alpha-ketobutyric acid in preparation of a medicine for preventing and / or treating vascular calcification. Through a high-phosphorus-induced vascular smooth muscle cell calcification model and a vitamin D3-induced mouse aorta calcification model, it is proved for the first time that alpha-ketobutyric acid can significantly inhibit vascular calcium salt deposition, reduce osteogenic transdifferentiation of vascular smooth muscle cells and down-regulate expression of osteogenic related markers such as RUNX2 and BMP2. In addition, the alpha-ketobutyric acid and the sodium hydrosulfide are combined for use to show a synergistic effect. The invention provides a new drug selection and strategy for prevention and treatment of vascular calcification and related cardiovascular diseases.

The application relates to an inhibitor targeting Cx43 and application. The inhibitor innovatively adopts natural hedyotis diffusa exosome as a core carrier, forms a complex through self-assembly with hyaluronic acid, and is further surface-modified with cationic chitosan to construct a ternary delivery system of "exosome-hyaluronic acid-chitosan". The system can efficiently load and protect therapeutic nucleic acid molecules, and significantly improve the in-vivo stability of the nucleic acid molecules. The hyaluronic acid endows the carrier with active targeting ability to bone tissue cells, and the chitosan improves the cell uptake efficiency. After the loaded miR-206 enters target cells, the expression of gap junction protein Cx43 can be specifically down-regulated, and then the ERK1 / 2-Runx2 signal path is regulated. The preparation shows good application potential in inhibiting Cx43.